These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 38310466)
1. Cuproptosis Related Gene Li X; Rui J; Yang Z; Shang-Guan F; Shi H; Wang D; Sun J Curr Cancer Drug Targets; 2024; 24(8):867-880. PubMed ID: 38310466 [TBL] [Abstract][Full Text] [Related]
2. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma. Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226 [TBL] [Abstract][Full Text] [Related]
3. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing. Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z Front Immunol; 2023; 14():1174762. PubMed ID: 37287976 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis identifies YKT6 as a potential prognostic and diagnostic biomarker in lung adenocarcinoma. Zhang L; Wang S; Wang L BMC Cancer; 2024 Oct; 24(1):1235. PubMed ID: 39375639 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma. Li R; Tong R; Zhang JL; Zhang Z; Deng M; Hou G J Cancer Res Clin Oncol; 2024 May; 150(5):246. PubMed ID: 38722401 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive bioinformatics analysis to identify a novel cuproptosis-related prognostic signature and its ceRNA regulatory axis and candidate traditional Chinese medicine active ingredients in lung adenocarcinoma. Wang S; Xing N; Meng X; Xiang L; Zhang Y Front Pharmacol; 2022; 13():971867. PubMed ID: 36110528 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation. Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014 [TBL] [Abstract][Full Text] [Related]
8. Prognostic signature of lung adenocarcinoma based on stem cell-related genes. Huang Z; Shi M; Zhou H; Wang J; Zhang HJ; Shi J- Sci Rep; 2021 Jan; 11(1):1687. PubMed ID: 33462260 [TBL] [Abstract][Full Text] [Related]
9. Upregulation of M6A Reader HNRNPA2B1 Associated with Poor Prognosis and Tumor Progression in Lung Adenocarcinoma. Wang W; Li S Recent Pat Anticancer Drug Discov; 2024; 19(5):652-665. PubMed ID: 37877146 [TBL] [Abstract][Full Text] [Related]
10. The High Expression of PTPRH Is Associated with Poor Prognosis of Human Lung Adenocarcinoma. Chen A; Ding S; Shen X; Lin X Comput Math Methods Med; 2021; 2021():9932088. PubMed ID: 34367321 [TBL] [Abstract][Full Text] [Related]
11. [Construction of Lung Adenocarcinoma Prognosis Model and Drug Sensitivity Analysis Based on Cuproptosis Related Genes]. Sun J; Zhang H; Liu H; Dong Y; Wang P Zhongguo Fei Ai Za Zhi; 2023 Aug; 26(8):591-604. PubMed ID: 37752539 [TBL] [Abstract][Full Text] [Related]
12. Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis. Sun D; Zhu Y; Zhao H; Bian T; Li T; Liu K; Feng L; Li H; Hou H Cell Oncol (Dordr); 2021 Oct; 44(5):1019-1034. PubMed ID: 34109546 [TBL] [Abstract][Full Text] [Related]
13. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma. Wu C; Rao X; Lin W Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma. Zhong Y; Jiang L; Lin H; Li X; Long X; Zhou Y; Li B; Li Z IUBMB Life; 2019 Jul; 71(7):942-955. PubMed ID: 30817091 [TBL] [Abstract][Full Text] [Related]
15. PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma. Gao Y; Luo L; Xie Y; Zhao Y; Yao J; Liu X Mol Carcinog; 2020 May; 59(5):503-511. PubMed ID: 32133692 [TBL] [Abstract][Full Text] [Related]
16. A Prognostic 14-Gene Expression Signature for Lung Adenocarcinoma: A Study Based on TCGA Data Mining. Liu J; Hou S; Wang J; Chai Z; Hong X; Zhao T; Sun Z; Bai L; Gao H; Gao J; Chen G Oxid Med Cell Longev; 2020; 2020():8847226. PubMed ID: 33414898 [TBL] [Abstract][Full Text] [Related]
17. Identification Six Metabolic Genes as Potential Biomarkers for Lung Adenocarcinoma. Zhang S; Lu Y; Liu Z; Li X; Wang Z; Cai Z J Comput Biol; 2020 Oct; 27(10):1532-1543. PubMed ID: 32298601 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer. Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115 [TBL] [Abstract][Full Text] [Related]
19. Characterization of an endoplasmic reticulum stress-associated lncRNA prognostic signature and the tumor-suppressive role of RP11-295G20.2 knockdown in lung adenocarcinoma. Yu L; Zhou S; Hong W; Lin N; Wang Q; Liang P Sci Rep; 2024 May; 14(1):12283. PubMed ID: 38811828 [TBL] [Abstract][Full Text] [Related]
20. Identification of PSMD11 as a novel cuproptosis- and immune-related prognostic biomarker promoting lung adenocarcinoma progression. Huang Q; Tian R; Yu J; Du W Cancer Med; 2024 Jun; 13(11):e7379. PubMed ID: 38859698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]